Other therapy.

Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retรจl Read More

2024-03-25T10:45:47-04:00June 18th, 2013|Adjuvant, Evidence, MammaPrint, MINDACT, Other|

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More

2024-03-25T10:47:25-04:00June 1st, 2013|Evidence, Healthcare Economics, MammaPrint, Other|

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More

2024-03-25T10:51:13-04:00November 1st, 2012|Evidence, Lobular, MammaPrint, Neoadjuvant, Other|

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Read More

2024-03-25T10:51:59-04:00August 15th, 2012|BluePrint, Evidence, Other, Validation|

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrintยฎ) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More

2024-03-25T10:52:27-04:00June 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37-47 AUTHORS: Read More

2025-04-04T16:53:01-04:00May 1st, 2012|BluePrint, Evidence, Neoadjuvant, Other, Validation|
Go to Top